Andersen supports the company transfer of Holoclar®
The legal professionals of Andersen Andrea di Castri, Partner, and Carlo Riso, Manager, supported Holostem Terapie Avanzate to find an agreement for Holoclar® business unit transfer.
Holostem Terapie Avanzate, is a spin-off of the University of Modena and Reggio Emilia and a biotechnological company specialized in the development, production, registration, and distribution of products for therapies based on cultures of epithelial stem cells for cell and gene therapy. Holostem Terapie Avanzate agreed with Chiesi Farmaceutici, an Italian multinational pharmaceutical company, to acquire the Market Authorization of Holoclar® issued by the European Medicines Agency (EMA).
Holoclar® is the result of the Italian research in the field of epithelial stem cell biology and represents an advanced therapy capable of restoring vision to patients with severe corneal burns.
Press release (in Italian): Legalcommunity.it, Diritto24.ilsole24ore.com, Cassa Forense Radiocore, Inhousecommunity.it, Milanofinanza.it.
